Description

Haemonetics Acquires Vivasure—Could This Be Its Next Growth Engine?

Haemonetics Corporation is making headlines with its recent strategic move to acquire Galway, Ireland-based Vivasure Medical—a developer of next-generation, fully absorbable, sutureless closure technologies for large-bore percutaneous procedures. The deal, announced in early January 2026, comprises an upfront payment of €100 million (~$110M), with up to €85 million (~$93M) in additional milestone-based payments. This marks a significant step forward for Haemonetics, which is looking to cement its footprint in structural heart and endovascular procedures through its Interventional Technologies (IVT) segment. The acquisition follows a transformative FY2026 performance, with the company expanding margins across segments, growing core products like TEG and NexSys, and showing renewed optimism in plasma collections and vascular closure. Despite recent softness in legacy VASCADE performance and esophageal cooling drag, Haemonetics is aggressively repositioning IVT for long-term growth—and Vivasure could be central to this strategy.